## HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BICALUTAMIDE safely and effectively. See full prescribing information

for BICALUTAMIDE. BICALUTAMIDE tablet, film coated for oral use

Bicalutamide tablets 50 mg is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D<sub>2</sub> metastatic carci-

noma of the prostate. Bicalutamide tablets 150 mg daily is not approved for use alone or with other tractmente. DOSAGE AND ADMINISTRATION \_\_\_\_

The recommended dose for bicalutamide therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening). (2) DOSAGE FORMS AND STRENGTHS

50 mn tablets (3) CONTRAINDICATIONS -

# Hypersensitivity (4.1) Women (4.2) Pregnancy (4.3 and 8.1)

WARNINGS AND PRECAUTIONS Severe hepatic charges and hepatic failure have been observed rarely. Monitor serum transaminase levels prior to starting treatment with bici-tutumide, at regular intervels for the list four modified or treatment and periodically threadure, and for symptoms or signs suggestive of hepatic dysfunction. Use bicalutamide with caution in patients with hepatic impairment. [5,1] upre-structure, use une-unitime winn caused in ghiefelt with height Opennetismed. Since the proceeding of the proceeding of the proceeding of the height proceeding of the height proceeding of the critical proceeding of the proceeding of the proceeding of the opening of the proceeding of the proceeding of the proceeding of the opening of the proceeding of the proceeding of the proceeding of the opening of the proceeding of the proceeding of the proceeding of the opening of the proceeding of the proceeding of the proceeding of the opening of the proceeding of the proceeding of the proceeding of the opening of the proceeding of the proceeding of the proceeding of the opening of the proceeding of the proceeding of the proceeding of the opening of the proceeding of the proceeding of the proceeding of the opening opening of the proceeding of the proceeding of the proceeding of the opening opening opening of the proceeding opening opening of the opening opening

ADVERSE REACTIONS

Adverse reactions that occurred in more than 10% of patients receiving calutamide plus an LHRH-A were: hot flashes, pain (including general, back *h/ki* and abdominal), asthenia, constipation, infection, nausee, periphera ferma, dyspneer, diarrhes, hematuria, nocturia and anemia. (6:1) To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.lda.gov/medwatch. DRUG INTERACTIONS

 B-bicalutamide is an Pr-bicalutamide is an inhibitor of CVP 3A4 (herefore, caution should be used when bicalutamide is co-administered with CVP 3A4 substrates. (7)
 Profitornothin times should be closely monitored in patient already receiv-ing coumarin anticoagulants who are started on bicalutamide. (7)

Pediatric patients: Labeling describing pediatric clinical studies for bicalutamide is approved for AstraZeneca Pharmaceuticats LP's bicalu-tamide tablet. However, due to AstraZeneca Pharmaceuticats LP's market-ing exclusivity rights, a description of those clinical studies is not approved for this bicalutamide labeling. (8.4)

See 17 for PATIENT COUNSELING INFORMATION Proposed Patient Labeling Provided FULL PRESCRIBING INFORMATION: CONTENTS



4.3. Pregnancy WARNINGS AND PRECAUTIONS

0.2. Postmarkening Experience DRUG INTERACTIONS USE IN SPECIFIC POPULATIONS

5.4. Laboratory Tests ADVERSE REACTIONS 6.1. Clinical Trials Expe

8.1. Pregnancy 8.3. Nursing Mothers 8.4. Pediatric Use 8.5. Geriatric Use 8.6. Hepatic Impairment 8.7. Renal Impairment

11. DESCRIPTION 12. CLINICAL PHARMACOLOGY

12.3. Pharmacokinetics 13. NONCLINICAL TOXICOLOGY

16.1. Storage and Handling 17 PATIENT COUNSELING INFORMATION

13. Noncentral
 13.1. Carcinogenesis, Mutagénesss, Impartument
 13.1. Carcinogenesis, Mutagénesss, Impartument
 14. CLINICAL STUDIES
 14.4. Récelutarnide tablets 50 mg Daily in Combination with an

LHRH-A
 LHRH-A
 Sufety Data from Clinical Studies using Bicalutamide 150 mg
 HOW SUPPLIED/STORAGE AND HANDLING

Sections or subsections omitted from the full prescribing information are not listed.

Gynecomastia and Breast Pain Glucose Tolerance

A SANDOZ **Bicalutamide Tablets** R, only

 $\oplus$ 



 INDICATIONS AND USAGE Bicalutamide tablets 50 mg daily are indicated for use in combination ther-apy with a lutenizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D\_ metastatic carcinoms of the prostate. Bicalutamide tablets 150 m other is not arcorrected for use along or with Bicalutamide tablets 150 mg daily is not approve other treatments (see CLINICAL STUDIES (14.2)). 2. DDSAGE AND ADMINISTRATION INDICATIONS AND USAGE -

recommended dose for bicalutamide therapy in co analog is one 50 mg tablet once daily (morring or flood. It is recommended that bicalutamide be take ty. Tratament with bical disensity. trainide therapy in combination with an oce daily (morning or evening), with or bicalufamide be taken at the same time ide should be started at the same time as treatment with an LHRH analog. Dosage Adjustment in Renal Impairment: to dosage adjustment is necessary for patients wil USE IN SPECIFIC POPULATIONS (8.7). Dosage Adjustment in Hepatic Impairment: to dosage adjustment is necessary for patients with miser imment. In patients with severe two impairment (n-% increase in the hall-life (5.9 and 10.4 days for in c ents with renal im: [see USE 2.2. Dos

potients, respectively of the active analysis of a constrained and impaired ment is necessary (see USE IN SPECIFIC POPULATIONS (8.6)). 3. DOSAGE FORMS AND STREMENTINS Bizatusmide 50 mg tablets for oral administration. 4. CONTRAINMOLATIONS

for use alone or with

Body System

Pelvic Pain

thest Pai

Hypertension

ulence

Anemia† Metabolic and Nutritiona

ripheral Edem right Loss perglycemia

Increased Weight G

one Pair

asthenia

Nervous System

nietv

Nausea

Body as a Whole

CONTINATIONATIONAL
 Thypersensitivity:
 Distribution of the drug or any other tablet's components, hypersensitivity reactions including angioneuroic elema and urticaria have been reported [see ADVERSE REACTIONS (6.2)].

: de has no indication for women, and should not be used in this

4.3. Preparage: Beatingnie muy cause tetal arms when administered to a preparate browner. Relationship is contrained used in when administered to a preparate broadbandie in the second and a preparate in the broadband to broadbandie. If this drug is used arms preparation, of it he patient becomes reparat which broadband he drugs preparatory of a the patient becomes preparation the broadband of the patient becomes the second and the second and the second and the patient becomes and the second second and the second and the second and the second second and the second second and the second second and the second and

Contrast, and Profectations:
 Contrast, and the profectations of the same of the properties of the same of the same of the properties of the same of the sa

39% of Diamits, respectively. 3. Glasses Effectives A reduction in glucose bierance: (HV) agoints: This my maintest as diabetes or loss of glycemic control left) agoints: This my maintest as diabetes or loss of glycemic control system to monitoring blood glucose in patients receiving bicatularinée in com-isation with LHPA agoints. 5. Laboratory Testa: Bagdair assessments of sarrum Prostate Specific Antigen (PSA) may be Regular assessments of sarrum Prostate Specific Antigen (PSA)

2. Association reason of a series Postate Specific Antigone (PSA) may be heading a monotonic part of the particular specific and the part of the pa

reflect the rates observed in practice. 6.1. Clinical Trials Experience: ... common mats experience: In patients with advanced prostate cancer treated with bicalutamide in cc bination with an LHRH analog, the most frequent adverse reaction was fracher. (52%) sames (35%). In the multicenter, double-blind, controlled clinical trial comparing bica-tamide 50 mg once daily with flutamide 250 mg three times a day, each combination with an LHRH analog, the following adverse reactions with in briddence of 55 or presetre reparatless of causality baw been remothed

Depression Regnizatory System 51 (13) 33 (8) 32 (8) 24 (6) 18 (4) 15 (4) 32 (8) 24 (6) 23 (6) 22 (3) 19 (5) ugh Increased Kfinitis Skin and Appendages 35 (9) 25 (6) 30 (7) 20 (5) Urogenita 49 (12) 48 (12) 35 (9) 55 (14) 26 (6) 36 (9) acuita aru Trart Infaction 36 (9) 27 (7) 23 (6) 30 (7) 35 (9) 15 (4) otence ast Pain Jrinary Frequency Jrinary Retention 23 (6) 20 (5) 19 (5) 29 (7) 14 (3) 15 (4)

Table 1. Incidence of Adverse Reactions (>5% in Either Treatmen Group) Regardless of Causality

Treatment umber of Pat

Analog (n=407)

69 (17) 58 (14)

46 (11 23 (6

22 (5) 29 (7) 32 (8)

53 (13) 45 (11)

19 (5) 29 (7) 32 (8)

Bicalutamide Plus LHRH Analog (n=401)

142 (35) 102 (25) 89 (22) 85 (21) 71 (18) 46 (11) 127 (31

34 (8) 29 (7)

211 (53) 217 (53)

34 (8) 29 (7)

87 (22) 62 (15)

49 (12) 30 (7) 30 (7) 07 (28

26 (6) 25 (6) 24 (6)

53 (13) 30 (7) 26 (6) 22 (5) 22 (5) 42 (10) 39 (10)

37 (9) 27 (7) 21 (5) 17 (4) 43 (11

41 (10) 31 (8) 27 (7) 35 (9) 40 (10) 39 (10)

20 (5) 16 (4) 9 (2) 33 (8)

15 (4) 32 (8) in AST. ALT or both. Urinary Incontinence Increased liver enzy : rme test includes i Increased inverteingen ess incluses increases in a status in AL in orioni. A menia inclusion samma, hypochronic- and non deficiency anemia. Other adverse reactions (greater than or equal to 2%), but less than 5%) reported in the bicatamanide. HRM stado treatment group are listed below by body system and are in order of decreasing frequency within each body system regardless of clausally. Body area Whate: Metoplasm, Reck Pain; Fever; Chills; Sepsis; Hernia; Cyst

Cardiovascular: Angina Pectoris; Congestive Heart Failure; Myocardial Infarct; Heart Arrest; Coronary Artery Disorder; Syncope

Digestive: Melena: Rectal Hemorrhage: Dry Mouth: Dysphagia: Gastrointestinal Disordar: Daviedontal Abscess: Gastrointestinal Carcinoma Disorder; Periodontal AbScess; base unnecessed Metabolic and Nutrilional: Edema; BUN Increased; Creatinine Increased; Dehydration; Gout;

vetes: pertonia; Confusion; Sommolence; Libido Decreased; Neuropathy; izatory; izatory; izatory; izatory;

Respiratory: Lung Disorder; Asthma; Epistaxis; Sinusitis Skin and Appendages: \_\_Dry Skin; Alopecia; Pruritus; Herpes Zoster; Skin Carcinoma; Skin

Special Senses: Cataract specified

Cararact specified Jrogenital: Dysuria; Urinary Urgency; Hydronephrosis; Urinary Tract Disorder Nonormal Laboratory Test Values:

Abnormal Laboratory Test Values: Laboratory abnormalities including elevated AST, ALT, bilirubin, BUN, and creatinine and decreased hemoglóbin and white cell count have been reported in both bicalutamide-LHRH analog treated and flutamide-LHRH analog treated patients. 6.2. Postmarketing Experience: The following adverse reactions h

the following adverse reactions have been identified during possa use of bicalutamide. Because these reactions are reported voluntari a population of uncertain size, it is not always possible to reliably e their frequency or establish a causal relationship to drug exposure.







and tetrahydrofuran. Bicolatamide is a noemate with its antiandrogenic activity being almost actuality particitied by Te He-maniformer of licalidamide; the S-entalitoner The inactive ingredients of briadizatimide tablets are construch, hyprome-lose, lactose monohydrate, magnetisum stearate, polyethyleine glycol, polycontex 80, posidere, acidium starch glycolate, and tabletamide tabletamide tabletamide and tabletamide acide anticities and tabletamide acide a

12. CLINICAL PHARMACOLOGY 12.1 Mechanism Of Action

(See Reverse)

## PATIENT INFORMATION **Bicalutamide Tablets**

The advector of a call of the information that and the advector of the advecto

What is bicalutamide tablets? Bicalutamide tablets is a prescription medicine called an androgen receptor inhibitor, used in combination with lut-neizing hormone-releasing hormone (LHRH) medicines to trait stage D<sub>2</sub> metatastic prostate cancer. It is not known if bica-lutamide tablets is said and effective in children. Who should not take bicalutamide tablets? Do not take bicalutamide tablets fit:

you are allergic to any of the ingredients in bicalutamide tablets. See the end of this leaflet for a complete list of ingre-

are pregnant or think you may be pregnant

ve diabetes (noor blood sugar control has been reported

icines may affect how bicalutamide tablets works. Know the medicines you take. Keep a list of your medicines with you to show your healthcare providers when you get a new

been established. Labeling describing pediatric circuit al tudies for bicalitumine is approved for AstraZeneca Pharmaceuticals LP's bicalistumist tablet. However, due to AstraZeneca Pharmaceuticals LP's mainling exclusivity rights, a descrip-tion of those circuit studies is not approved for the bicalistumide labeling. In those studies in patients given SD or 150 mg daily, no assignment and control between age and desay-state levels of total bicalistamide or the active Pervanitioner the bisen shown. How should I take hiralutamide tablets?

tending between use and standy-statik keels of bold bicatumide or the acrow F-maniformer has been shown.
8.6 Hegalic lengamment: Bouldamide to been shown.
9.6 Hegalic lengamment: Bouldamide to be shown of the statistic is not provery manufactories by the statistic statistic statistic is not provery manufactories by the statistic statistic statistic statistic statistic statistic by the statistic statistic statistic statistic statistic statistic statistic statistic manufactories and statistic sta

Theament is a second to be a second

ease (n-4). 8.7. Renal Impairment: Renal Impairment (as measured by creatinine clearance) had no signif-icant effect on the elimination of total bicalutamide or the active R-enantiomer.

common cases of hypersensitivity reactions, including angioneurotic and uticaria [see CONTRAINDICATIONS (4.1)], and uncommon cases

I interstitial lung disease, including interstitial preumonitis and pulmonary brosis, have been reported with bicalutamide. Reduction in glucose tolerance, manifesting as diabetes or a loss of voemic control in those with pre-existing diabetes, has been reported dur-

glycemic control in mose temperature of the second second

2. Detti ili 1646. una di URI ili anti constanti ili di una di una di una di una di una di una di URI ili anti anti constanti in el provinci, il una di una la di si di una una di una comuni attercagnati ten tuna di una di una di una di una comuni attercagnati ten tuna di una di una di una di una comuni attercagnati ten tuna di una di una di una di una comuni attercagnati con di una comuni attercagnati con di una comuni attercagnati con di una comuni attercagnati con di una di u

LUE: IN SPECIFIC POPULATIONS
 Linearing and the second se

mathematical of an anotogen receiptor initialized could alread on evenopment in animal representation basiles, music effecting of rats receiving does of 10 mg/sg (approximate); 20 of music response the recommode of any sg (approximate); 20 of music response to the recommode propulsation. There are a set of the the set of the

Bicautamore is not indicated for use in women. 8.4 Pediatric Use The safety and effectiveness of bicalutamide in pediatric patients have not been extractive band


may be necessary. 8. USE IN SPECIFIC POPULATIONS

cant effect on the elimit 8.8. Women: Bicalutamide has not been studied in women. 10. OVERDOSAGE

19. OVFMDDSAcE Long-term clinical trials have been conducted with dosages up to 200 mg of bicablamide daily and these dosages have been well tolerated. A single doe of bicablamide that results in symptoms of an overdose considered to be it for threatening has not been established. There is no specific antidoter, treatment of an overdose should be

In the management of an overdose with bicalutamide, vomiting may be duced if the patient is alert. It should be remembered that, in this patient induced if the patient is alert. It should be remembered that, in this patient opoulation, multiple drugs may have been taken. Dialysis is not likely to be helpful since bicalutamide is highly protein bound and is extensively inetab-oliced. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.

and close observat 11 DESCRIPTION Bicalutamide tablets for oral administration contain 50 mg of bicalutamide, non-steroidal androgen receptor inhibitor with no other known endocrine tor-stepdal anarogen receptor innotor with no other known emborni livity. The chemical name is propanamide, N- [4-cyano-3 -(trifluc netty[t]ptenty]-3- [(4-fluoropheny])salfory[]-2-tydroxy-2-methyl-,(+-e structural and empirical formulas are:



Bicalutamide tos a molecular weight of 430.37. The pKa' is approximately 12. Bicalutamide is a fine white to off-white powder which is practically insol-able in water at 37°C (5 mg per 1000 mL), slightly soluble in ochoroform and absolute thanol, sparingly soluble in methods in actoros

echanism UI Action Itamide is a non-steroidal androgen receptor inhibitor. It competi-hibits the action of androgens by binding to cytosol androgen s in the target tissue. Prostatic carcinoma is known to be andro-4

PATIENT INFORMATION

**Bicalutamide Tablets** 

Read the Patient Information that comes with bicalutat

The other action in the second second

Bicalutamide tablets is a prescription medicine called an

you are allergic to any of the ingredients in bicalutamide ablets. See the end of this leaflet for a complete list of ingre-

utamide tablets? Before you take bicalutamide tablets, tell your healthcare provider about all your medical conditions including if you: are a woman (see who should not take bicalutamide tablets)

are pregnant or think you may be pregnant

Take bicalutamide tablets exactly as prescribed.
 Take bicalutamide tablets at the same time everyday.

Your treatment with bicalutamide tablets should start at the same time as your treatment with the LHRH medicine.

If you miss a dose do not take an extra dose, take the next dose at your regular time. Do not take 2 doses at the same

.ime. Bicalutamide tablets can be taken with or without food.

If you take too much bicalutamide tablets, call your health-care provider or Poison Control Center or go to the nearest

hospital emergency room right away. Do not stop taking bicalutamide tablets unless your health-

care provider tells you. Your healthcare provider may do blood tests while you take bicalutamide tablets

Your prostate cancer may get worse while taking bicalu-

tamide tablets in combination with LHRH medicines. Regular

monitoring of your prostate cancer with your healthcare

provider is important to determine if your disease is worse. Vhat should I avoid while taking bicalutamide tablets? Driving and operating machinery. Do not drive, operate nachinery, or do other dangerous activities until you know how icalutamide tablets affects you.

Dicalutamide tablets arrects you. What are the possible side effects of bicalutamide tablets?

swelling in your ankles, legs or feet

· feeling dizzy

ou are a woman

PATIENT INFORMATION

**Bicalutamide Tablets** 

ead the Patient Information that comes with bicalut

The other allower handhord mark and the other with obtainable tablets before you start taking it and each time you get a refil. There may be new information. This leaflet does not take the place of taking with your healthcare provider about your med-ical condition or your treatment. What is bicalutamide tablets?

Bicalutamide tablets is a prescription medicine called an

you are allergic to any of the ingredients in bicalutamide tablets. See the end of this leaflet for a complete list of ingre-

dients What should I tell my healthcare provider before taking bica-lutamide tablets?

Iutamide tablets? Before you take bicalutamide tablets, tell your healthcare provider about all your medical conditions including if you: are a voroma (see worb should not table bicalutamide tablets) - are pregnant or think your may be pregnant - have liver problems - take a medicine to thin your blood. Ask your healthcare provider or pharmacki ff your en ot sure if your medicine

a blood thinner. Ive diabetes (poor blood sugar control has been reported

have diabetes (poor blood sugar control has been reported in people taking bicalutarized baltes in combination with Light medicines)
 including prescription and comprescription medicines, yota taka including prescription and non-prescription medicines, vitamiss and hertaal supplements. Bicalutamide tablets and other med-cines may affect the way other medicines work, and other medicines may affect the way other medicines work, and other medicines may affect the vision of ther medicines work, and other medicines may affect the vision of ther medicines work, and other medicines may affect the vision of thermedicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and other medicines may affect the vision of the medicines work, and the medicines work and the medicines w

Know the medicines you take. Keep a list of your medicines with you to show your healthcare providers when you get a new

 Your treatment with bicalutamide tablets should start at the same time as your reatment with the LHRH medicine. If you miss a dose do not take an extra dose, take the next dose at your regular time. Do not take 2 doses at the same

time. Bicalutamide tablets can be taken with or without food. Bicalitatinude tablets can be taken with or without tool. If you take too much bicalutanide tablets, call your health-care provider or Poison Control Center or go to the nearest hospital emergency room right away. Do not stop taking bicalutamide tablets unless your health-

care provider tells you. Your healthcare provider may do blood tests while you take bicalutamide tablets.

Your prostate cancer may get worse while taking bicalu

tamide tablets in combination with LHRH medicines. Regular monitoring of your prostate cancer with your healthcare

provider is important to determine if your disease is worse. **Vhat should I avoid while taking bicalutamide tablets?** Driving and operating machinery. Do not drive, operate nachinery, or do other dangerous activities until you know how icalutamide tablets affects you.

What are the possible side effects of bicalutamide tablets?

The art is the participant of the system of the second sec

The most common side effects of bicalutamide tablets include: hot flashes, or short periods of feeling warm and sweating whole body pain in your back, pelvis, stomach feeling weak

(See Beverse)

ination

swelling in your ankles, legs or feet diarrhea

diarrhea
blood in your urine
waking from sleep to urinate at night
a decrease in red blood cells (anemia)

infection

· feeling dizzy

(See Beverse)

 $\oplus$ 

Take bicalutamide tablets exactly as prescribed. Take bicalutamide tablets at the same time everyday.

How should I take hiralutamide tablets?

Bicalutamide tablets is a prescription medicine called an androgen receptor inhibitor, used in combination with lut-enzing hormone-releasing hormone (LHRH) medicines to treat stage D-metatastic prostate cancer. It is not known if bica-lutamide tablets is safe and effective in children. Who should not take bricalutamide tablets? Do not take bicalutamide tablets if:

/ou are a woman

is a blood th

Read the Patient Information that comes with bicaluta

Bicalutamide tablets is a prescription medicine called an androgen receptor inhibitor, used in combination with lut-enizing hormone-releasing hormone (LHRH) medicines to treat stage D<sub>2</sub> metatastic prostate cancer. It is not known if bica-lutamide tablets is safe and effective in children. Who should not take bicalutamide tablets? Do not take bicalutamide tablets if ou are a woman

dients What should I tell my healthcare provider before taking bica-lutamide tablets? dients What should I tell my healthcare provider before taking bica-

utamide tablets? Before you take bicalutamide tablets, tell your healthcare provider about all your medical conditions including if you: are a woman (see who should not take bicalutamide tablets)

take a medicine to thin your blood. Ask your healthcare nrovider or pharmacist if you are not sure if your medicine

have liver problems take a medicine to thin your blood. Ask your healthcare provider or pharmacist if you are not sure if your medicine is a blood thi s a blood th s a blood thinner. ave diabetes (poor blood sugar control has been reported

have diabetes (poor blood sugar control has been reported in people taking bicalutarized baltes in combination with Lifelt medicines)
 including prescription and non-prescription medicines; you take including prescription and non-prescription medicines; you take and herefal supplements. Bicalutarixide tablets and other med-cines may affect the way other medicines work, and other medicines may affect the way other medicines work, and other medicines may affect the way other medicines work, and other medicines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work, and other med-ticines may affect the way other medicines work and and affect the medicines work and a state of the medicines work and and a state tables medicines work and a state of the medicines work and and affect tables medicines work and and a state of the medicines work and and a state tables medicines work and and affect the medicines work and a state tables medicines work and affect tables works.

have diabetes (poor blood sugar control has been reported in people taking bicaltariatic tablets in combination with LIRRI medicines)
 port healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vilamits and herals suppriserines. Sicultariante tablets and other med-cines may affect each other causing side effects. Bicalutamide tablets may affect leach other causing side effects. Bicalutamide

Know the medicines you take. Keep a list of your medicines with you to show your healthcare providers when you get a new How should I take hisalutamide tablets?

 Take bicalutamide tablets exactly as prescribed.
 Take bicalutamide tablets at the same time everyday. Your treatment with bicalutamide tablets should start at the same time as your treatment with the LHRH medicine.

same time as your reatment with the LHHH medicine. If you miss a dose do not take an extra dose, take the next dose at your regular time. Do not take 2 doses at the same time. Bicalutamide tablets can be taken with or without food.

If you take too much bicalutamide tablets, call your health-care provider or Poison Control Center or go to the nearest

hospital emergency room right away. Do not stop taking bicalutamide tablets unless your health-

Do tild sop samp decaration water and the second se tamide tablets in combin on with LHRH medicines. Regular monitoring of your prostate cancer with your healthcare provider is important to determine if your disease is worse. hat should I avoid while taking bicalutamide tablets?

Driving and operating machinery. Do not drive, operate achinery, or do other dangerous activities until you know how icalutamide tablets affects vou. Dicalutamide tablets affects you. What are the possible side effects of bicalutamide tablets?

wina zie nie possuie sole enerce o i uciautamie taeles z Bicalutamie tablet can cause serious sole effects. Get medical help right away, if you haw: r utoleb breahing with o without a cough er fever. Some peo-ple who take bicalutamide tablets get an inflammation in the lungs called interstital lung disease. An allergic reaction. Symptoms of an allergic reaction include: richnig of the skin, hives (riased bumps), swelling

What are the possible side directs of bicalclamide tablet? Bicultariation bibles can cause acrisol uside flexits. Cost medical help right away, if you have the second strain of the second strain second strain terms pleve to bab bickardine tablets grant information in the important second strain second strain second strain of the face, lips, tongue, threat, or trouble swallowing. \* Vellowing of the sing and every faunch, the second strain of the face, lips, tongue, threat, or trouble swallowing. \* Vellowing of the sing and every faunch, bearings, loss of paper of the face, lips, tongue, threat, or trouble swallowing. \* Point blood sugar control can happen in people who bake black-ter strained strained strained grant and the site plane. \* Point blood sugar control can happen in people who bake black-entingement of the strained (syncematics) and hereast gain \* Point blood sugar control can happen in people who bake black-entingement of the strained (syncematics) and hereast gain \* Point blood sugar control can happen in people who bake black-entingement of the strained (syncematics) and hereast gain \* Point blood sugar control can happen in people who bake black-tentingement of the strained (syncematics) and hereast gain \* Point blood sugar control can happen in people who have bake black-tentingement of the strained (syncematics) and hereast gain \* Point blood sugar control can happen in people who have bake black-\* Point blood sugar control can happen in people who have bake black-\* Point blood sugar control can happen in people who have bake black-\* Point blood sugar control can happen in people who have bake black-\* Point blood sugar control can happen in people who have bake black-\* Point blood sugar control can happen in people who have bake black-\* Point blood sugar control can happen in people who hap include: tiching of the skin, hives ( raised bumps), sveiling of the face, lips, to nough, tirot, of trouble swallowing, Yellowing of the skin and eyes (jaundice), dark urine, right upper stomach pain, nausea, vorming, tiredness, loss of appetite, chills, fever, whole body pain. These may be symp-tums of liver damage. Poor blood sugar control can happen in people who take bica-huamide tables in combination with LHRH medicines.

lutamide tablets in combination with LHRH medicines. enlargement of breast (gynecomastia) and breast pain enlargement of breast (gynecomastia) and breast pain

Consequences or uneast (gynecomastia) and breast pain The most common side effects of bicalutaride tablets include hoft fashes, or short periods of feeling warm and sweating whole body pain in your back, pelvis, stomach feeling ware constipation Consequences to uneast (gynecomastia) and breast pain The most common side effects of bicalutamide tablets include: hot flashes, or short periods of feeling warm and sweating whole body pain in your back, pelvis, stomach feeling wark constipation infection

(See Beverse)

infection welling in your ankles, legs or feet diarrhea
blood in your urine
waking from sleep to urinate at night
a decrease in red blood cells (anemia)

 diarrhea
 blood in your urine
 waking from sleep to urinate at night
 a decrease in red blood cells (anemia) · feeling dizzy

nausea

## (Continued)

 $\oplus$ 

# Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of bicalutamide tablets. For more information, ask your healthcare provider or

pharmacist. Call your doctor for medical advice about side effects. You may report side effects to EDA at 1-800-FDA-1088. How should I store bicalutamide tablets? Store at 20-25°C (68°-77°F) (see USP Controlled Room

Temperature). KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHIL-

DREN. General information about the safe and effective use of bica-lutamide tablets. Medicines are sometimes prescribed for purposes other

Medicines are sometimes prescribed for purposes other than those iside in a patient information latel. Do not use bic-lutandi tables for a condition for which it was not prescribed. Do not give bicalizationed tables to those pool, even it flow This patient information latellar so those pool, even it flow This patient information about bicalizationed tables tak with your hatithcare provider. You can aky own hatthcare provider planmatics for information about bicalizationed tables tak it with 000-558-572. What are the ingredients in halautamise tables! Active ingredients include: backlutamise tables!

What are the ingredients in bicalutamide tablets? Active ingredients include: bicalutamide. Inactive ingredi-ents include: corn starch, hypormellose, lactose monohydrate, magnesium starate, polyethylene glycol, polysorbate 80, povi-done, sodium starch glycolate, and titanium dioxide. 06-2009M

Sandoz Inc. Princeton, NJ 08540

2.

## (Continued) Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of bicalutamide tablets. For more information, ask your healthcare provider or

pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should 1 store bicalutamide tablets? Store at 20°-25°C (68°-77°F) (see USP Controlled Room

# Temperature). KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHIL-

Sandoz Inc. Princeton, NJ 08540

# Temperature). KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHIL-

<text><text><text><text><text><text>

(Continued)

# Sandoz Inc. Princeton, NJ 08540

Tell your healthcare provider if you have any side effect that

bothers you or that does not go away. These are not all the possible side effects of bicalutamide tablets. For more information, ask your healthcare provider or

pharmacist. Call your doctor for medical advice about side effects. You may report side effects to EDA at 1-800-EDA-1088.



The short of priority who have been by table due the backflamme and any the short of priority of the short of

*	Parameter	Mean	Standard Deviation
	Normal Males (n+30)		
	Apparent Oral Clearance (L/hr)	0.320	0.103
	Single Dose Peak Concentration (mcg/mL)	0.768	0.178
	Single Dose Time to Peak Concentration (hours)	31.3	14.6
	Half-life (days)	5.8	2.29
	Patients with Prostate Cancer (n=40)		
- i -	Css* (mcg/mL)	8.939	3.504
- E	* Css=Mean Steady-State Concentration		
	13. NONCLINICAL TOXICOLOGY		

13. BORLINGLE IDDRCG OF The Carcingenetic Reducential, supportant of Forthigh Carcingenetic Reducential, supportant of the Carcingenetic Reduced State (1998) and the State (1998) and the Carcingenetic Reduced State (1998) and the State (1998) and the Carcingenetic Reduced State (1998) and the <text><text><text><text><text><text>

1.1. Similar, it statistis Sim gulary in Communities with an in-manification, control of the statistic Sim gulary in Communities with an in-amalicizetti, advanced prototale cancer were andonauxie to result beachamies Sim gues with (44 patients) in the statistic statistic prototale instatistic statistic statistic statistic statistic statistic protein in containing and statistic statistic statistic statistic statistic matching, 21(2):771 patients theta with Schulzminet-Holm and/op matching, 21(2):771 pa

Figure 1. The Kaplan-Meier probability of death for both antiandrogen treatment groups.

------ Bicalutamide plus LHRH-A

Days to death There was no significant difference in time to objective tumor progres-sion between treatment groups (see Figure 2). Objective tumor progression was defined as the appearance of any bone metadatase or the worsening of any existing born emidadates to hore scan-mibilitable in weither data (see a see a more by CS) or on more of any relati-metadatase of the worsening of the second second second second metadatase of the worsening of the second second second metadatase of the worsening of the second second second pression of bicautiantie gluss LHRH analog to that of theamide gluss LHRH analog was 0.53 (Sec) scotterione interval, 0.75 to 1.10.

Figure 2. Kaplan-Meier curve for time to progression for both antiandrogen treatment groups.

------ Bicalutamide plus LHRH-A ------ Flutamide plus LHRH-A

730 1095 Days to progression

Duality of life was assessed with self-administered patient questionnaires on pair, social functioning, emotional well being, vitality, activity limitation, de disability, overall health, physical capachy, general symptoms, and treatment related symptoms. Assessment of the Duality of Life questionnaires did no indicate considerat agintizatti differences between the two treatment

groups. 14.2. Safety Data from Clinical Studies using Bicalutamide 150 mg Bicalutamide 150 mg is not approved for use either alone or with other

Bicalutarnide 150 mg is not approved for use either alone or with öther treatments. Two identical multicenter, randomized, open-label trials comparing bica-lutarnide 150 mg däily monotherapy to castration were conducted in patients that had locally advanced (13-4, NK, MO) or metstatic (MT) patients that had locary arrange transmission of the set of the s

respectively. Locally Advanced (73-4, NX, MO) Group Biolalamne's 550 mg daily and approved for use in patients with locally advanced (73-4, NK, MO) cancer of the vasible. Following discontinuation of all MT patients, the traits continued with the T3-4, NK, MD patients units data (comparison: the target ratin (R3-2K), the risk of data was 25%, INR 125, INR-10, D3-2K and T3-11 lighter in the biolastication groups paid in the smaller target ratio and the target ratin (R3-4K). Since (R3-4K) and R3-4K 125, INR-10, D3-2K and T3-11 lighter in the biolastication groups paid in the smaller with the biolastication and main states (R3-4K). The R3-4K and R3-4K

----- Flutamide plus LHRH-A 730 1095 Days to death

B 0.3

0.9

0.6

5 0.4 0.3

å 0.2

0.0 365

1460 182

1460

with LHRH agonists. Consideration should therefore be given to monitor-ing blood glucose in patients receiving bicalutamide tablets in combination with LHRH agonists.

## PATIENT INFORMATION RICAL UTAMIDE TABLETS

Read the Patient Information that comes with localization bables before product. This latest does not take the patient of taking any take the product of the latest set of take the patient of taking any take the product any take the patient of taking any take the product any take the patient of taking any take the patient of takes the patient of take the patient of takes the patient of takes the patient of takes the take the patient of takes th

It is not khown if bacalutanide tables date and effective in children. Who should not table blcalutanide tables date and effective in children. Uno store the statistication of tables tables to be not table statistication blcalutaria. • you are allerigic to any of the ingredients in hichatamids tablets. See the end of this kalifier of a complete ital ingredients What should 1 fell my healthcare provider before taking bicalutamide tablet?

The second secon

right away. Do not stop taking bicalutamide tablets unless your healthcare provider

telis you. Your healthcare provider may do blood tests while you take bicalutamide tablets. Your prostate cancer may get worse while taking bicalutamide tablets in combination with LHRIH medicines. Regular monitoring of your prostate cancer with your healthcare provider is important to determine if your dis-tancer with your healthcare provider is important to determine if your dis-tancer with your beathcare provider is important to determine if your dis-tablets.

Chico wers of works. esse is works. What should I avoid while taking bicalutamide tablets? Driving and operating machinery. Do not drive, operate machinery, or do other dangerous activities until you know how bicalutamide tablets

do offittel camperous accurves unit you note the detection of affects you. What are the possible side effects of bicalutamide tablets? Bicalutamide tablets can cause serious side effects. Get medical help right away, if you have: to trouble breathing with or without a cough or fever. Some people who take bicalutamide tablets get an inflammation in the lungs called interstitial lung citates.

disease. An allergic reaction. Symptoms of an allergic reaction include: itching of the skin, hives ( raised bumps), swelling of the face, lips, tongue, throat, off the Skini, intere ( tableto Europa, amering of two energy energy and the skini and eyes ( Skini and eyes ( Skini Ski

emaignment or breast (gymechanism) and breast pain The most common side effects of bicalitation industrials tablets include: hot flashes, or short periods of feeling warm and sweating whole body pain in your back, pelvis, stomach seeing weak constipation

\* Index
 \* Index
 \* Index
 \* Standard Structure and March, lega or feet
 \* Standard Structure and March, lega or feet
 \* Standard Structure and March and Structure and Structure

Constraints intervation accord the sine af the data set of the size of the statistication of the Macroson set of the statistication of the statistication

Sandoz Inc. Princeton, NJ 08540

The electric particle of the a hard off of the CG 90% CG 90% 137. Becatamatic black, to creat adventification, and support at the electric particle of the adventification of the electric particle as 220 of the revenue size, this cased with a dist support at 220 of the revenue size, this cased with a dist support at 220 of the revenue size, this cased with a dist support at 220 of the revenue size, this cased with a dist support at 220 of the revenue size, this cased with a dist support at 220 of the revenue size, this cased with a dist support at 220 of the revenue size, this cased with a dist support at 220 of the revenue size, this cased with a dist support 220 of the revenue size, the revenue size of the revenue size of the 220 of the revenue size, the revenue size of the revenue size of the 220 of the revenue size of the revenue size of the revenue size of the revenue size of the 220 of the revenue size of the reve

nel interrupt or stop taking these mediciations without consulting their phraces. The stop of the sto

The distribution of the statement of the problem of the distribution of the statement of th

patientis versus 279 (32.9%) déaths in the placebo treated patients (local ized watchful waiting group) for a hazard ratio of 1.16 (95% Cl 0.99 to 1.37) 16. HOW SUPPLIED/STORAGE AND HANDLING

06-2009M 7340

1-6. Based on a maxim age 70 kg patient.

dose of 50 mg/day of bicalutamide for an ave